ArticleBiomedical chromatography : BMC2026
A Simple and Sensitive LC-MS/MS Method for Simultaneous Quantification of Dasatinib and Erythromycin in Mice Plasma: Application to Preclinical Pharmacokinetic Study.
Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dasatinib (DAS) is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) and erythromycin (ERY) is macrolide antibiotic used to treat a range of inflammatory conditions are often co-administered in clinical practice. The simultaneous estimation of DAS and ERY helps in understanding the pharmacokinetics and drug-drug interactions. In this respect, we presented novel, sensitive, and validated bio-analytical LC-ESI-MS/MS method for simultaneous estimation of DAS and ERY in CD-1 mice plasma. The LLOQ was 2.0 ng/mL with an S/N ratio of 15. This validated method was used to study the PK of DAS and ERY in mice following intravenous and oral administration. The DAS was administered at 5 mg/kg via both oral and intraveneous route, whereas ERY was administered at 50 mg/kg orally and 5 mg/kg intraveneousaly. Following intravenous dosing, DAS showed high clearance and distribution, while ERY exhibited high clearance and distribution. The oral bioavailability was 64% for DAS and 21% for ERY. When co-administered orally at 5 mg/kg for DAS and 50 mg/kg of ERY, the AUC and C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.